Select Language

GSK-3beta

GSK-3beta Overview

English Name	Glycogen synthase kinase-3 beta	Approved Drugs	0
Drugs in Clinical Trials	4	Target Synonym	EC 2.7.11，EC:2.7.11.26，EC:2.7.11.1，Serine/threonine-protein kinase GSK3B，Glycogen synthase kinase-3 beta，GSK3B，Glycogen Synthase Kinase 3 Beta，GSK-3 Beta，GSK3beta Isoform，EC 2.7.11.26，EC 2.7.11.1
Highest Development Stage	Phase 3 Clinical

English Name	Glycogen synthase kinase-3 beta
Target Synonym	EC 2.7.11，EC:2.7.11.26，EC:2.7.11.1，Serine/threonine-protein kinase GSK3B，Glycogen synthase kinase-3 beta，GSK3B，Glycogen Synthase Kinase 3 Beta，GSK-3 Beta，GSK3beta Isoform，EC 2.7.11.26，EC 2.7.11.1
Approved Drugs	0
Drugs in Clinical Trials	4
Highest Development Stage	Phase 3 Clinical

GSK-3beta Product List

Product Category
Protein (1)
Product Status
Launched (1)
Species
Human (1)
Tag
His Tag (1)
Conjugate
Unconjugated (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
GSB-H5545	Human	InsectCells	Human GSK-3beta / GSK-3β Protein, His Tag (active enzyme, MALS verified)

Total: 1

GSK-3beta Background

Glycogen synthase kinase-3 (GSK-3) is a pivotal molecule in the development of Alzheimer's disease (AD). GSK-3beta is involved in the formation of paired helical filament (PHF)-tau, which is an integral component of the neurofibrillary tangle (NFT) deposits that disrupt neuronal function, and a marker of neurodegeneration in AD.

GSK-3beta Synonyms

GSK3B,Glycogen synthase kinase-3 beta

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Tideglusib	NP-12; AMO-02; NP-031112	Phase 3 Clinical	Noscira Sa	Alzheimer Disease; Amyotrophic Lateral Sclerosis; Autism Spectrum Disorder; Cardiomyopathies; Myotonic Dystrophy	Details
Ruboxistaurin Mesilate Hydrate	LY-333531; REC 3599; SM 030	Phase 2 Clinical	Eli Lilly And Company	Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic macular oedema; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Gangliosidoses, GM2; Heart Failure; Hyperpigmentation; Melanosis	Details
Elraglusib	9-ING-41	Phase 2 Clinical	Actuate Therapeutics Inc, Northwest University, University Of Illinois At Chicago	Adenocarcinoma; Bone metastases; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Colorectal Neoplasms; Dermatofibrosarcoma; Diffuse Intrinsic Pontine Glioma; Glioma; Hemangiosarcoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia-Lymphoma, Adult T-Cell; Liposarcoma; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Meningioma; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Osteosarcoma; Pancreatic Neoplasms; Primary Myelofibrosis; Rhabdomyosarcoma; Salivary Gland Neoplasms; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial	Details
Asnuciclib	CDKI-73; LS-007; QHRD-107	Phase 2 Clinical	Shandong University, University Of South Australia	Leukemia, Myeloid, Acute	Details